NCT03472963View on ClinicalTrials.gov

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

March 29, 2019

Study Completion Date

March 29, 2019

Conditions
HIV Infections
Interventions
DRUG

Single dose of Genvoya® and a single 800 mg dose of Darunavir®

Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Trial Locations (1)

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER

NCT03472963 - Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. | Biotech Hunter | Biotech Hunter